Coherus Bio (NQ: CHRS )
5.270 +0.290 (+5.82%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2023 Add to My Watchlist
Headline News about Coherus Bio
Various names in the biotech sector are seeing a substantial increase in search activity today. Such names include the likes of Akebia Therapeautics, Corvus Pharmaceuticals, and Mirati Therapeutics.
Via Talk Markets
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'
June 01, 2023
One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug...
Coherus BioSciences Earnings Preview
May 05, 2023
Coherus BioSciences's Return On Capital Employed Overview
March 09, 2023
A Preview Of Coherus BioSciences's Earnings
March 03, 2023
Looking Into Coherus BioSciences Return On Capital Employed
August 17, 2022
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 09, 2023
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease.
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
February 18, 2023
Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of...
Via Talk Markets
Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket
December 23, 2022
Gainers Expion360 Inc. (NASDAQ: XPON) shares rose 152% to $2.47 in pre-market trading. Expion360 been selected as the exclusive supplier of high-energy lithium ion batteries for an overland trailer...
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following